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Objective: To manage patients with dysfunctional uterine bleeding (DUB) according to 
endometrial thickness.
Methods: A retrospective chart review of 49 patients who reported 8 or more days of bleeding 
was performed. They were then divided into three groups based on endometrial thickness (mm): 
less than 6, 6–11, and greater than 11. These three groups were treated with combined oral 
contraceptive pills (OCP), conjugated estrogen plus progesterone and megestrol respectively. 
Patients given megestrol also underwent endometrial biopsy before treatment. Patients recorded 
the degree of bleeding each day for one month after starting treatment.
Results: Mean endometrial thickness in the combined OCPs, conjugated estrogen plus 
  progesterone and megestrol groups were 4, 8 and 14 mm, respectively. Combined OCPs 
decreased bleeding from 46 to 8 days (P , 0.05, n = 8). Conjugated estrogen plus proges-
terone decreased the number of days of bleeding from a mean of 41 to 9 (P , 0.01, n = 16). 
  Megestrol decreased bleeding from 54 to 3 days (P , 0.001, n = 25). 52% of patients given 
megestrol had endometrial hyperplasia.
Conclusion: These results support the effectiveness of treating patients with DUB according 
to endometrial thickness.
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Introduction
Dysfunctional uterine bleeding (DUB) is a common debilitating problem amongst 
women in all age groups and accounts for 20% of gynecology office visits.1 It is defined 
as abnormal, irregular bleeding (excessively heavy, prolonged, or frequent intervals of 
bleeding) in the absence of demonstrable pelvic disease, complications of pregnancy 
or systemic disease.2–5 The exact mechanism is uncertain but is thought to be caused 
by dysfunction of hypothalamic-pituitary-ovarian axis.6
Diagnosis can be made by excluding intrauterine pathology like submucosal myo-
mas and polyps using transvaginal sonogram (TVS) or saline infusion sonogram (SIS). 
TVS has lower sensitivity and specificity in detecting intrauterine abnormalities com-
pared to SIS. However an approach using endometrial thickness measurement by 
TVS to further determine the diagnostic and treatment options is an effective and 
non invasive way to triage premenopausal patients with DUB.7 In postmenopausal 
women with abnormal bleeding, the role of endometrial thickness measurement is 
well established and a 4–5 mm cut off value has a high negative predictive value in 
excluding endometrial hyperplasia or cancer.8 The current medical options for initial International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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management of DUB are based on clinical presentation and 
severity and include high dose estrogens, combined estrogen 
and   progesterone or progesterone alone. However there is 
insufficient data regarding their dose, duration and effective-
ness and the treatment usually requires a trial of one of more 
available options.
The objective of our study is to investigate the utility of 
treating dysfunctional uterine bleeding based on endometrial 
thickness instead of solely on clinical presentation. The 
goal is to determine if tailoring hormone therapy to endome-
trial thickness as detected by TVS improves the management 
of this condition.
Material and method
This study is a retrospective chart review of patients 
with   dysfunctional uterine bleeding (DUB) who received 
medical treatment in our reproductive endocrinology   service. 
The study was approved by Institutional Review Board 
of SUNY Downstate Medical center and Kings County 
Hospital Center.
DUB was diagnosed in presence of excessive,   prolonged, 
or frequent intervals of bleeding for eight or more 
days,   unrelated to anatomic lesions or systemic disease. 
A complete history and physical examination was performed 
and routine laboratory tests were obtained to exclude sys-
temic causes of bleeding. All patients underwent TVS to 
exclude uterine pathology and to assess the endometrial 
thickness (ET).
Patients without underlying anatomic or systemic 
  pathology were offered hormonal treatment based on 
  endometrial thickness. The management scheme is   outlined 
in Figure 1. Patients with endometrial thickness of less than 
6 mm were treated with combination of Ethinyl estradiol 
0.035 mg and norgestimate 0.25 mg, one pill daily for 28 days. 
Patients with endometrial thickness of 6–11 mm were treated 
with conjugated estrogen 2.5 mg PO twice daily for one week 
then 2.5 mg PO once daily for next week followed by 1.25 mg 
PO once daily for further two weeks. Medroxyprogesterone 
pill 10 mg was also given for the last two weeks. Patients 
with endometrial thickness of 12 mm or greater underwent 
endometrial biopsy to exclude malignancy and were treated 
with megestrol acetate 40 mg daily. In event of endometrial 
carcinoma, patients were referred to gynecology–oncology 
service. All the three groups of patients also received 
azithromycin to prevent and treat endometritis secondary to 
prolonged bleeding.
Patients were given menstrual calendars to grade 
bleeding each day for one month beginning at the onset of 
treatment. Grading system was as follows: 0 – no   bleeding, 
1 – scanty bleeding, 2 – moderate bleeding, 3 – heavy 
  bleeding, and 4 – heavy bleeding with clots. A bleeding 
score was calculated by adding all grades on calendar for 
the entire month. Fifty premenopausal patients with DUB 
who were treated as described above were included. Patients 
with bleeding disorders or with intrauterine pathology like 
fibroids, polyps, or endometrial cancer were excluded from 
the study. 
Eligible patients were divided into three groups 
based on endometrial thickness and treatment offered. 
Group I (ET , 6 mm), Group II (ET 6–11 mm), Group III 
(ET . 12 mm). For all patients information regarding age, 
BMI, age at menarche, cycle regularity and frequency, endo-
metrial thickness, number of days of bleeding prior to treat-
ment, number of days of bleeding after onset of treatment, 
and bleeding score were recorded. For patients in Group III 
results of endometrial biopsy were also recorded.
Comparison of the patient characteristics for all three 
groups was made using repeated measures ANOVA (SPSS, 
version 16) with P value of 0.05 and confidence interval 
set at 95%. The difference between mean number of days 
of bleeding prior to treatment and at the onset of treatment 
was also compared for all three groups using ANOVA pair 
wise comparisons. Student t-test was used to compare patient 
characteristics for patients with and without endometrial 
hyperplasia within Group III.
Results
Retrospective chart review of 50 patients was performed. 
Menstrual diary for one patient was not available and was 
excluded from the study. Patient characteristics are sum-
marized in Table 1. Mean patient age was 28 ± 1.0 years 
and was similar in all three groups. Mean BMI was 
34 ± 1.3 and approached significant positive correlation 
with endometrial thickness (r = 0.281, P = 0.056). BMI 
also positively correlated with number of days of bleeding 
prior to treatment (r = 0.343, P , 0.05).The mean number 
of days of bleeding prior to treatment was similar in all 
three groups. 75% of patients reported irregular menstrual 
cycles consistent with anovulatory bleeding. Mean endo-
metrial thickness for combined OCP (n = 8), conjugated 
estrogen + progesterone (n = 16) and megestrol acetate 
(n = 25) groups were 4.2 ± 0.3, 8.0 ± 0.5, and 14.1 ± 2.6 mm 
respectively.
All three treatments significantly decreased the number 
of days of bleeding after onset of treatment. Combined 
OCPs decreased the number of days of bleeding from International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Discussion
TVS is an excellent non-invasive tool to diagnose anatomic 
causes of dysfunctional uterine bleeding.9 A study by 
de Vries et al recommends evaluation of endometrial thick-
ness by TVS as initial approach for premenopausal patient 
with DUB.7 For patients with ET of greater than 5 mm, SIS 
is recommended to further determine the need for diagnostic 
hysteroscopy and to determine appropriate treatment options. 
Another study by Batzer supports TVS as an effective method 
to determine the need and type of surgical treatment for 
patients with DUB.10 Traditionally however TVS has a limited 
role in medical treatment of DUB if any.
Our literature search in PUBMED and MEDLINE 
revealed no mention of prior studies investigating the util-
ity of endometrial thickness as detected by TVS in medical 
treatment of DUB.
We obtained significant reduction in duration and severity 
of bleeding by tailoring hormonal treatment based on endo-
metrial thickness cut off values. We used monophasic OCPs 
for ET less than 6 mm based on underlying etiopathogenesis. 
A thin endometrial stripe is a result of denuded endometrium 
secondary to prolonged bleeding. The estrogen component of 
OCP stimulates uniform endometrial growth and promptly 
stops shedding, while the progesterone component stabilizes 
the endometrium by converting it into pseudodecidua.11
With increasing ET between 6–11 mm we used oral 
conjugated estrogen followed by progesterone to stabilize 
the estrogen stimulated endometrial growth. The mechanism 
of action of conjugated estrogen is similar to intravenous 
estrogen and acts by stimulating clotting at the capillary 
level.12 Added advantage of using oral conjugated estrogen 
is the ability to treat patients in an outpatient setting.
For ET more than 11 mm we used megestrol acetate, 
which is a powerful antiestrogen known to prevent and reverse 
endometrial hyperplasia.13
Amongst the three treatment regimens, megestrol acetate 
was the fastest at suppressing uterine bleeding from a mean of 
54 days to 3 days with the lowest bleeding score (4.9 ± 1.1). 
It was equally effective for treating both patients with and 
without endometrial hyperplasia who had ET of more than 
11 mm.
Use of megestrol for treatment of endometrial hyperplasia 
is well known however no previous studies have compared 
megestrol with other hormonal therapies for treatment 
of DUB.
A randomized clinical trial by Munro et al compared oral 
medroxyprogesterone with combined OCPs and found them 
equally effective in treating acute uterine bleeding.14 Their 
Table1 Patient demographic and clinical characteristics
Treatment 
groups
Combined 
OCPs 
(n = 8)
Conjugated 
estrogen + 
progesterone 
(n = 16)
Megestrol 
(n = 25)
Age (years) 23 ± 2 29 ± 2 29 ± 1
BMI 29 ± 3 32 ± 2 37 ± 2
Menarche (years) 12 ± 0.5 12 ± 0.5 12 ± 0.3
Cycle regularity (%) 25% 25% 20%
Number of  
cycles per year
9 ± 2 7 ± 1 7 ± 1
Endometrial  
thickness (mm)
4.2 ± 0.8 8.0 ± 0.5 14.2 ± 0.6
Number of days of  
bleeding prior  
to treatment 
46 ± 14 41 ± 8 54 ± 8
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Figure 2 Number of bleeding before and after hormonal therapy.
a mean of 46 ± 14 days to 8 ± 3 days (P , 0.05). Conjugated 
estrogen and progesterone decreased the number of days 
of bleeding from a mean of 41 ± 8 days to 9 ± 2 days 
(P = 0.001). Megestrol decreased bleeding from 54 ± 8 
days to 3 ± 7 days (P , 0.001). Improvement in uterine 
bleeding with the three different treatments is plotted in 
Figure 2.
Bleeding score was found to be lowest in megestrol group 
(4.9 ± 1.1) compared to other two groups (Figure 3).
Patient characteristics of patients with and without 
endometrial hyperplasia were compared within megestrol 
group as shown in Table 2. Endometrial hyperplasia was 
seen in 52% of patients within group III. Those patients with 
endometrial hyperplasia had a significantly higher mean 
BMI (40.8 ± 3.1) than those without (31.7 ± 1.8, P , 0.05). 
There was no significant difference in either the number of 
days bleeding prior to or after treatment between these two 
subgroups. There was also no significant difference in the 
bleeding score between them.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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study was limited by a small sample size and was unable to 
demonstrate statistically significant difference in between 
the treatment regimens. In contrast to our study, they utilized 
high dose regimen for initial one week followed by low dose 
for additional three weeks.
Another randomized controlled trial by Devore et al15 
compared intravenous conjugated estrogens with placebo 
in patients with acute uterine bleeding and found significant 
reduction in bleeding with conjugated intravenous   estrogens. 
We used oral conjugated estrogens for patients with endo-
metrial thickness between 6 mm to 11 mm, and in contrast 
to intravenous estrogen, patients can be treated on an out-
patient basis.
Endometrial biopsy was performed in our study for 
ET greater than 11 mm and endometrial hyperplasia was 
detected in more than fifty percent of patients in this group. 
A study by Paraskevaidis et al showed an   endometrial 
thickness cut off values of 13 mm has sensitivity, 
  specificity, and positive predictive value of 100%, 71.6%, 
and 40.6% respectively to detect endometrial   abnormalities 
in   perimenopausal women.16 Another recent study by 
  Getpook et al showed that ET of 8 mm or less is unlikely 
to be associated with malignant pathology.17 Although 
we were able to establish the presence of endometrial 
  hyperplasia in those with thick endometrium, we were 
not able to exclude it in those with thinner endometrium 
stripes (less than 11 mm).
Incidence of endometrial hyperplasia in our study group 
was 26.5% (n = 13). This was significantly higher than the 
incidence of endometrial hyperplasia in premenopausal 
women in general quoted as 2%–10%.18
Mean BMI in our study was 34 with significant positive 
correlation with endometrial thickness. Higher BMI was also 
noted in patients with endometrial hyperplasia. This find-
ing supports obesity and increased BMI as a risk factor for 
anovulatory bleeding and endometrial hyperplasia.16 It can 
also be suggested that patients with higher BMI who suffer 
from anovulatory bleeding may need endometrial biopsy 
regardless of endometrial thickness.
The primary strength of our study was that patients 
within the three groups had similar demographic and 
Table  2  Characteristics  of  patients  treated  with  megestrol 
acetate
Group No endometrial 
hyperplasia 
(n = 12)
Endometrial 
hyperplasia 
(n = 13)
Age (years) 29 ± 3 29 ± 2
BMI 31.8 ± 1.8 40.1 ± 3.4
Endometrial thickness (mm) 14.5 ± 0.6 13.8 ± 0.9
Number of bleeding days prior 
to treatment
42 ± 5 66 ± 14
Number of bleeding days 
after treatment
3 ± 1 3 ± 1
Bleeding score 4.4 ± 1.8 5.4 ± 1.5
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clinical   characteristics with only significant difference in 
their   endometrial thickness. Although our sample size was 
small, we were able to get significant reduction in bleeding 
values in all three groups. The principal limitation was the 
lack of controls for each group. Randomized prospective trial 
will be needed to further substantiate our findings.
In summary we conclude that management of DUB based 
on endometrial thickness is an effective approach to control 
acute uterine bleeding. Our study emphasizes on the medical 
treatment of acute DUB only. Further evaluation is recom-
mended to determine the need for management of patients 
with chronic DUB.
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